DOCSLIB.ORG

Product List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Product List PRODUCT LIST PHARMA API THERAPEUTIC CLASS CEP ORIGIN ABACAVIR SULPHATE NRTI India ABIRATERONE ACETATE Antiandrogen India ACEBUTOLOL HCL Antianginal – Antihypertensive – Spain Antiarrhythmic AL HYDROXIDE MG CARBONATE CO-DRIED Antacid Germany GEL ALENDRONATE SODIUM Bone diseases India ALFACALCIDOL Bone diseases Taiwan ALMASILATE Antacid Germany ALOSETRON HYDROCHLORIDE Irritable Bowel Syndrome India ALPROSTADIL (PROSTAGLIANDIN E1) Erectile dysfunction Ungary ALUMINIUM HYDROXIDE (ALUGEL) Antacid Germany ALUMINIUM PHOSPHATE Antacid Germany AMANTADINE HCI Antiviral – Antiparkinsonian Spain AMANTADINE SULPHATE Antiviral – Antiparkinsonian Spain AMBRISENTAN Pulmonary Arterial Hypertension India AMLODIPINE BESILATE Antianginal – Antihypertensive Spain ANAGRELIDE HYDROCHLORIDE Antitrombotic India ANASTROZOLE Breast Cancer India APIXABAN Anticoagulant Canada APREPITANT Antiemetic Spain ARFORMOTEROL TARTRATE Antiasthmatic - COPD India ARTEMETHER Antimalarial India ARTESUNATE Antimalarial India ARTICAINE OR CARTICAINE Local Anesthetic- Antiarrhythmic Spain ATAZANAVIR SULPHATE Antiretroviral Agent India ATORVASTATIN CALCIUM Antihyperlipidemic China ATORVASTATIN CALCIUM TRIHYDRATE Antihyperlipidemic China / India ATOVAQUONE Antimalarial Spain ATRACURIUM BESYLATE NMBA Spain ATROPINE BASE Anticholinergic Spain ATROPINE SULFATE Anticholinergic Spain BALSALAZIDE DISODIUM DIHYDRATE Gastroenterology - Antiulcera Taiwan BECLOMETHASONE DIPROPIONATE Pulmonary desease - Antiasthma India BENAZEPRIL HCL ACE Inhibitor Spain BENZOCAINE Local anesthetic Italy BENZONATATE Antitussive Taiwan BERAPROST SODIUM Vasodilator Ungary BETAMETHASONE DIPROPIONATE Corticosteroid Malaysia FLARER S.A. Via Giuseppe Corti 5 - 6828 Balerna (Switzerland) - Tel: +41 91 912 31 81 - www.flarer.ch 1 PRODUCT LIST BETAMETHASONE SODIUM PHOSPHATE Corticosteroid Malaysia BETAMETHASONE VALERATE Corticosteroid Malaysia BICALUTAMIDE Antiandrogen India BISOPROLOL FUMARATE Antihypertensive Spain BORTEZOMIB Antineoplastic India BOSENTAN Antihypertensive India BROMPHENIRAMINE MALEATE Antihistaminic India BUDESONIDE Anti-Inflammatory India BUPIVACAINE HYDROCHLORIDE Local Anesthetic - Antiarrhythmic Spain BUPRENORPHINE BASE Analgesic India BUPRENORPHINE HCL Analgesic India BUSPIRONE Ansiolitic Germany CABERGOLINE Antiparkinsonian Canada CALCIPOTRIOL ANHYDROUS Antipsoriatic Taiwan CALCIPOTRIOL MONOHYDRATE Antipsoriatic Taiwan CALCITRIOL Antipsoriatic - Calcium Regulator Taiwan CALCIUM ACETATE Antihyperphosphatemia Taiwan CAPECITABINE Antineoplastic India CAPSAICIN Analgesic Taiwan CAPTOPRIL ACE Inhibitor Spain CARBALDRATE Antacid Germany CARBOCYSTEINE Mucolytic Spain CARBOPLATIN Anticancer India CARVEDILOL Antihypertensive Spain CEFACLOR Antinfective India CEFALEXIN MONOHYDRATE Antibiotic India CEFIXIME Antibiotic India CELECOXIB Analgesic India CELIPROLOL HCI Antianginal - Antihypertensive Spain CETIRIZINE Antihistaminic India CHLORPHENAMINE MALEATE Antihistaminic India CHOLINE FENOFIBRATE Antihyperlipidemic Spain CICLESONIDE Anti-Inflammatory India CICLOPIROX Antifungal Finland CICLOPIROX OLAMINE Antifungal Finland CINACALCET Calcium Regulator India CISATRACURIUM BESILATE NMBA Spain CISPLATIN Anticancer India CITALOPRAM HYDROBROMIDE Antidepressant India CODEINE BASE Analgesic Spain CODEINE HYDROCHLORIDE Analgesic Spain CODEINE MONOHYDRATE Analgesic Spain CODEINE PHOSPHATE HEMIHYDRATE Analgesic Spain CODEINE SULPHATE Analgesic Spain FLARER S.A. Via Giuseppe Corti 5 - 6828 Balerna (Switzerland) - Tel: +41 91 912 31 81 - www.flarer.ch 2 PRODUCT LIST CYCLOSPORINE Immune Suppressant Canada CYPROTERONE ACETATE Anticancer India DABIGATRAN ETEXILATE MESYLATE Anticoagulant Canada DACLATASVIR Antiviral India DANAZOL Endocrine-Metabolic Agent India DARIFENACIN HYDROBROMIDE Urinary Antispasmodic India DARUNAVIR ETHANOLATE Antiretroviral Agent India DARUNAVIR HYDRATE Antiretroviral Agent India DECITABINE Antineoplastic Spain DEFERASIROX Iron Chelation India DESLORATADINE Antihistaminic Spain DEXMEDETOMIDINE Sedative France DEXTHROMETHORPHAN HBR Cough Suppressant India DIACETYLMORPHINE BASE Opioid Maintenance Terapy Spain DIACETYLMORPHINE HYDROCHLORIDE Opioid Maintenance Terapy Spain DIMENHYDRINATE Antihistaminic - Anticolinergic Germany DOCETAXEL Antineoplastic Agent India DOCETAXEL TRIHYDRATE Antineoplastic Agent India DOLASETRON MESYLATE Antiemetic Spain DOLUTEGRAVIR SODIUM Antiretroviral Agent India DONEPEZIL HYDROCHLORIDE Cholinesterase Inhibitor India DOXAZOSIN MESYLATE Antihypertensive India DOXERCALCIFEROL Parathyroid Hormone Antagonist Taiwan DRONEDARONE Antiarrhythmic Spain DROPERIDOL Antipsychotic France DULOXETINE HYDROCHLORIDE Anitdepressant India DUTASTERIDE Benign Prostatic Hypertrophy Agent India EFAVIRENZ Antiretroviral Agent India EMTRICITABINE Antiretroviral Agent India ENALAPRIL MALEATE ACE inhibitor Spain ENALAPRILAT ACE inhibitor Spain ENTACAPONE Antiparkinsonian Spain ENTECAVIR Antiviral Canada ENTECAVIR MONOHYDRATE Antiviral India ENZALUTAMIDE Antinandrogen Spain ERLOTINIB HYDROCHLORIDE Antineoplastic Agent India ESCITALOPRAM OXALATE Antidepressant India ESCULIN Various France ESOMEPRAZOLE MAGNESIUM DIHYDRATE Gastric Acid Secretion Inhibitor India ESOMEPRAZOLE MAGNESIUM Gastric Acid Secretion Inhibitor India TRIHYDRATE ETHAMBUTOL HYDROCHLORIDE Tuberculosis India ETHINYLESTRADIOL Estrogen Replacement - India Antineoplastic FLARER S.A. Via Giuseppe Corti 5 - 6828 Balerna (Switzerland) - Tel: +41 91 912 31 81 - www.flarer.ch 3 PRODUCT LIST ETOPOSIDE Antineoplastic Agent India EVEROLIMUS Antineoplastic Agent Spain EXEMESTANE Antineoplastic Agent India EZETIMIBE Antihyperlipidemic Canada FAMCYCLOVIR Antiviral India FELODIPINE Calcium Channel Blocker India FENOFIBRATE Antihyperlipidemic Spain FEXOFENADINE HCL Antihistaminic Spain FINASTERIDE Alopecia Agent India FLUCONAZOLE Antifungal India FLUDIAZEPAM Anxiolytic Taiwan FLUPENTIXOL 2HCL Neuroleptic agent Taiwan FLUPIRTINE MALEATE Analgesic Spain FLUTAMIDE Antiandrogen India FLUTICASONE PROPIONATE Anti-inflammatory India FLUVOXAMINE MALEATE Antidepressant Canada FOSAPREPITANT DIMEGLUMINE Antiemetic Spain GADODIAMIDE Radiological Non-Ionic Contrast Taiwan Media GADOTERATE MEGLUMINE Paramagnetic Ionic Contrast Agent Taiwan GEFITINIB Antineoplastic Spain GEMCITABINE HCL Antineoplastic India GENTISATE SODIUM Anti-inflammatory France GIMERACIL Anticancer Taiwan GLATIRAMER ACETATE Central Nervous System Agent India GLYCOPYRRONIUM BROMIDE Antispasmodic India GRANISETRON BASE Antiemetic India GRANISETRON HYDROCHLORIDE Antiemetic India HYALURONIC ACID Various Italy HYDROTALCITE Antacid compounds Germany IMATINIB MESYLATE Antineoplastic Agent Canada IPRATROPIUM BROMIDE Respiratory Agent India IRBESARTAN Cardiovascular Spain IRINOTECAN HCL Antineoplastic Agent India IVABRADINE HYDROCHLORIDE Cardiovascular Agent India IXABEPILONE Antineoplastic Agent Taiwan KETAMINE HYDROCHLORIDE Anesthetic Adjunct India LAMIVUDINE Antiretroviral Agent India LAMOTRIGINE Anticonvulsant India LANSOPRAZOLE Antiulcerative Spain LANTHANUM CARBONATE HYDRATE Antihyperphosphatemia Canada LAPATINIB DITOSYLATE Antineoplastic Agent Taiwan LEFLUNOMIDE Immune Suppressant India LENALIDOMIDE Antineoplastic India FLARER S.A. Via Giuseppe Corti 5 - 6828 Balerna (Switzerland) - Tel: +41 91 912 31 81 - www.flarer.ch 4 PRODUCT LIST LETROZOLE Anticancer India LEVALBUTEROL HYDROCHLORIDE Bronchodilator India LEVALBUTEROL SULPHATE Bronchodilator India LEVALBUTEROL TARTRATE Bronchodilator India LEVETIRACETAM Antiepileptic India LEVOCETIRIZINE DIHYDROCHLORIDE Antihistaminic India LEVOFLOXACIN Antibiotic India LEVOMETHADONE HYDROCHLORIDE Opioid India LEVONORGESTREL Contraceptive Taiwan LIDOCAINE BASE Local Anesthetic-Antiarrhythmic Spain LIDOCAINE HCI Local Anesthetic-Antiarrhythmic Spain LINAGLIPTIN Hypoglycemic India LINEZOLID Antibiotic Taiwan LISINOPRIL ACE inhibitor Spain LOPINAVIR Antiretroviral Agent India LORATADINE Antihistaminic Spain LOTEPREDNOL ETABONATE Ophthalmologic Agent India LUBIPROSTONE Laxative Canada MAGALDRATE Antacid compounds Germany MAGNESIUM HYDROXIDE (GILUMAG) Antacid compounds Germany MAGNESIUM LACTATE DIHYDRATE Magnesium Supplement Spain MAXACALCITOL Antipsoriatic - Calcium Regulator Taiwan MEBEVERINE HYDROCHLORIDE Antispasmodic Belgium MELITRACEN Antidepressant Taiwan MELOXICAM Anti-inflammatory India MEMANTINE HYDROCHLORIDE Central Nervous System Agent Canada MEPIVACAINE HYDROCHLORIDE Local Anesthetic-Antiarrhythmic Spain MEPYRAMINE MALEATE Antihistaminic India METFORMIN HCL Type 2 Diabetes Spain METHADONE HYDROCHLORIDE Opioid Maintenance Terapy India METHOTREXATE Antineoplastic Spain METOPROLOL SUCCINATE Antihypertensive Spain METOPROLOL TARTRATE Antihypertensive Spain METRONIDAZOLE Antibiotic Poland MILRINONE PDE3 inhibitor Spain MIVACURIUM CHLORIDE NMBA Spain MOEXIPRIL HCL ACE inhibitor Spain MOMETASONE FUROATE Corticosteroid India MOMETASONE FUROATE ANHYDROUS Dermatoses, season allergic rhinitis India MONTELUKAST SODIUM Antiasthmatic Taiwan MORPHINE HYDROCHLORIDE Narcotic Analgesic Spain MORPHINE SULPHATE Narcotic Analgesic Spain MYCOPHENOLATE MOFETIL Immunosuppressant Canada N-ACETYLCYSTEINE Mucolytic Spain FLARER S.A. Via Giuseppe Corti 5 - 6828 Balerna (Switzerland) - Tel: +41 91 912 31 81 - www.flarer.ch 5 PRODUCT LIST NADOLOL Cardiovascular Agent Canada NAPROXEN Anti-inflammatory India NARATRIPTAN HYDROCHLORIDE Antimigraine Canada NATEGLINIDE Hypoglycemic India NEVIRAPINE Antiretroviral Agent India NEVIRAPINE HEMIHYDRATE Antiretroviral Agent India NIFEDIPINE Antianginal-Antihypertensive Spain NIFUROXAZIDE Antidiarrheal Spain NONIVAMIDE Hyperemic
Load more

Recommended publications
  • A Comparative Study of Neuromuscular Blocking Effects
    IndianJournalofAnesthesiaandAnalgesia OriginalResearchArticle January–February2020;7(1)(Part-I):58-63 DOI:http://dx.doi.org/10.21088/ijaa.2349.8471.7120.9 AComparativeStudyofNeuromuscularBlockingEffectsandReversibility ofCisatracuriumandVecuronium DivyaNKheskani1,HeenaSChhanwal2,BhaktiSJain3 1AssistantProfessor,2ProfessorandHead,3rdYearResident,DepartmentofAnaesthesia,GCSMedicalCollege,Hospital&Research Centre,NearChamundaBridge,Ahmedabad,Gujarat380025,India. Abstract Context: Cisatracurium is a cis isomer of parent compound atracurium, devoid of histamine release, thus possessing hemodynamic & cardiovascular stability. Aims: We compared the intubating conditions, hemodynamic stability & recovery of atracurium & vecuronium. Settings and Design: We carried out prospective, double blind randomized study after approval of ethical committee. 100 adult patients of ASA 1 &2with comparable demographicdatawereselected. Dividedin TwoGroupsC(Cisatracurium) &V(Vecuronium).Standardmonitoringwasdone&followingroutinepremedication&inductionagents, patientswereintubatedat2minsafteradministrationofcisatracurium0.15mg/kg&vecuronium0.1mg/ kgrespectively,maintainedonintermittentdoseofcisatracurium:0.03mg/kg&vecuronium:0.02mg/kg. IntubationconditionswereassessedaccordingtoTimeto25%recoveryoft1/tcfollowinginitialdoses,Time to25%recoveryoft1/tcfollowingrepeatedboluses,Timeto25%recoveryoft1/tcfollowinglastdose,Return oft4/t1ratio0.8spontaneousrecoveryatendofoperation.Statisticalanalysisused:Theresultswereevaluated byapplyingpairedt-testandp-valueusingSPSSStatisticalSoftware.Results:Intubatingconditionsat2mins
    [Show full text]
  • WO 2010/015655 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 11 February 2010 (11.02.2010) WO 2010/015655 Al (51) International Patent Classification: sham Research Centre, Wimblehurst Road, Horsham C07C 233/79 (2006.01) C07D 277/42 (2006.01) West Sussex RH 12 5AB (GB). SVIRIDENKO, Lilya C07C 255/58 (2006.01) A61K 31/166 (2006.01) [GB/GB]; Novartis Horsham Research Centre, Wimble C07C 311/39 (2006.01) A61K 31/427 (2006.01) hurst Road, Horsham West Sussex RH 12 5AB (GB). C07D 213/74 (2006.01) A61K 31/44 (2006.01) (74) Agent: VOEGELI-LANGE, Regina; Novartis Pharma C07D 213/75 (2006.01) A61P 1/00 (2006.01) Ag, Patent Department, CH-4002 Basel (CH). C07D 213/84' (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/EP2009/060150 AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (22) International Filing Date: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, 5 August 2009 (05.08.2009) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (25) Filing Language: English KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (26) Publication Language: English ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (30) Priority Data: SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, 08162006.4 7 August 2008 (07.08.2008) EP TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar
    USOO896.9514B2 (12) United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar. 3, 2015 (54) AGONISTS OF GUANYLATECYCLASE 5,879.656 A 3, 1999 Waldman USEFUL FOR THE TREATMENT OF 36; A 6. 3: Watts tal HYPERCHOLESTEROLEMIA, 6,060,037- W - A 5, 2000 Waldmlegand et al. ATHEROSCLEROSIS, CORONARY HEART 6,235,782 B1 5/2001 NEW et al. DISEASE, GALLSTONE, OBESITY AND 7,041,786 B2 * 5/2006 Shailubhai et al. ........... 530.317 OTHER CARDOVASCULAR DISEASES 2002fOO78683 A1 6/2002 Katayama et al. 2002/O12817.6 A1 9/2002 Forssmann et al. (75) Inventor: Kunwar Shailubhai, Audubon, PA (US) 2003,2002/0143015 OO73628 A1 10/20024, 2003 ShaubhaiFryburg et al. 2005, OO16244 A1 1/2005 H 11 (73) Assignee: Synergy Pharmaceuticals, Inc., New 2005, OO32684 A1 2/2005 Syer York, NY (US) 2005/0267.197 A1 12/2005 Berlin 2006, OO86653 A1 4, 2006 St. Germain (*) Notice: Subject to any disclaimer, the term of this 299;s: A. 299; NS et al. patent is extended or adjusted under 35 2008/0137318 A1 6/2008 Rangarajetal.O U.S.C. 154(b) by 742 days. 2008. O151257 A1 6/2008 Yasuda et al. 2012/O196797 A1 8, 2012 Currie et al. (21) Appl. No.: 12/630,654 FOREIGN PATENT DOCUMENTS (22) Filed: Dec. 3, 2009 DE 19744O27 4f1999 (65) Prior Publication Data WO WO-8805306 T 1988 WO WO99,26567 A1 6, 1999 US 2010/O152118A1 Jun. 17, 2010 WO WO-0 125266 A1 4, 2001 WO WO-02062369 A2 8, 2002 Related U.S.
    [Show full text]
  • The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection
    The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection - Country Reports Japan International Corporation of Welfare Services (JICWELS) Contents 1. Cambodia 1 2. Indonesia 70 3. Malaysia 91 4. Philippines 116 5. Sri Lanka 141 6. Thailand 161 The Study Programme for the Quality Management of Essential Medicines - Good Manufacturing Practical (GMP) and Inspection - Cambodia -1- KINGDOM OF CAMBODIA Nation Religion King Ministry of Health Department of Drugs and Food Country Report The Study Program on Quality Management of Essential Medicines Good Manufacturing Practice (GMP) and Inspection November 4, 2012 – November 30, 2012 Sponsored by : The Government of Japan Japan International Cooperation Agency (JICA) Department of Drugs and Food Ministry of Health, Cambodia. -2- I- COUNTRY PROFILE -3- A-Geography Cambodia is an agricultural country located in South East Asia which bordering the Gulf of Thailand, between Thailand, Vietnam, and Laos. Its approximate geographical coordinates are 13°N 105°E. Its 2,572 km border is split among Vietnam (1,228 km), Thailand (803 km) and Laos (541 km), as well as 443 km of coastline. Cambodia covers 181,035 square kilometers in the southwestern part of the Indochina, Cambodia lies completely within the tropics; its southernmost points are only slightly more than 10° above the equator. The country is bounded on the north by Thailand and by Laos, on the east and southeast by Vietnam, and on the west by the Gulf of Thailand and by Thailand. It consists of the Tonle Sap Basin and the Mekong Lowlands. To the southeast of this great basin is the Mekong Delta, which extends through Vietnam to the South China Sea.
    [Show full text]
  • Cost Analysis and Safety Comparison of Cisatracurium and Atracurium in Patients Undergoing General Anesthesia
    Eur opean Rev iew for Med ical and Pharmacol ogical Sci ences 2013; 17: 447-450 Cost analysis and safety comparison of Cisatracurium and Atracurium in patients undergoing general anesthesia A. MOVAFEGH, S. AMINI*, H. SHARIFNIA, H. TORKAMANDI*, A. HAYATSHAHI*, M. JAVADI* Intensive Care Unit, and *Pharmaceutical Care Department; Dr. Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran Abstract. – BACKGROUND : Non-depolarizing Introduction neuromuscular blocking agents (NMB) differ in pharmacokinetic and pharmacodynamic parame - The introduction of neuromuscular blocking ters. An anesthesiologist according to these simi - larities and differences is able to choose the least agents in 1942 into anesthetic practice was an im - costly one if the same safety profile and same clin - portant development. Non-depolarizing NMB ical benefit achieved with the different alternatives. agents differ in the onset of action, duration of ac - AIM: The main objective of this study is to eval - tion, metabolic route, potency, adverse effects and uate the economic and adverse drug reactions cost. An anesthesiologist is able to choose NMB prevalence and differences between cisatracurium drugs according to these similarities and differ - and atracurium the two non-depolarizing NMB 1,2 drugs, which are widely used in adult patients un - ences . Atracurium and Cisatracurium are two dergoing surgery with general anesthesia in a non-depolarizing NMB agents with intermediate teaching Hospital in Iran. duration of action 1. Cisatracurium besilate is the MATERIALS AND METHODS : A cost analysis R-cis isomer of atracurium besilate and is 3-4 fold and adverse drug reactions (ADR) monitoring more potent than atracurium 3. Compared with were performed.
    [Show full text]
  • Safety Data Sheet
    SAFETY DATA SHEET 1. Identification Product identifier TWINRIX ADULT Other means of identification Synonyms TWINRIX ADULT INJECTION 720 EL U AND 20 MCG/ML * TWINRIX SUSPENSION FOR INJECTION * TWINRIX ADULT PRE-FILLED SYRINGE * TWINRIX ERWACHSENE AMPULLE MIT 1 ML SUSPENSION * TWINRIX ERWACHSENE FERTIGSPRITZE MIT 1 ML SUSPENSION * HAB ADULT (720/20) * COMBINED HEPATITIS A/HEPATITIS B VACCINE * TWINRIX VACUNA COMBINADA ANTIHEPATITIS A Y B * TWINRIX VACUNA CONTRA LA HEPATITIS A Y B * TWINRIX ADULTO * AMBIRIX * HEPATITIS A VIRUS ANTIGEN (HM175) AND r-DNA HEPATITIS B SURFACE ANTIGEN (HBsAg) COMBINED VACCINE Recommended use Medicinal Product This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant to medicinal use of the product. In this instance patients should consult prescribing information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate safety data sheet for each ingredient. Recommended restrictions No other uses are advised. Manufacturer/Importer/Supplier/Distributor information COMPANY NAME GlaxoSmithKline US Address: 5 Moore Drive Research Triangle Park, NC 27709 USA Telephone: +1-888-825-5249 (General Inquiries) Email: [email protected] Website: www.gsk.com EMERGENCY CONTACTS CHEMTREC EMERGENCY NUMBERS Telephone: +(1) 703 527 3887 (International) 24/7; multi-language response Contract Number: CCN9484 VERISK 3E GLOBAL INCIDENT RESPONSE Telephone: +(1) 760 476 3971 (In country) +(1) 760 476 3962 or +(1) 866 519 4752 (International) 24/7; multi-language response Contract Number: 334878 2.
    [Show full text]
  • The Role of Antispasmodics in Managing Irritable Bowel Syndrome
    DOI: https://doi.org/10.22516/25007440.309 Review articles The role of antispasmodics in managing irritable bowel syndrome Valeria Atenea Costa Barney,1* Alan Felipe Ovalle Hernández.1 1 Internal Medicine and Gastroenterology specialist Abstract in San Ignacio University Hospital, Pontificia Universidad Javeriana, Bogotá, Colombia. Although antispasmodics are the cornerstone of treating irritable bowel syndrome, there are a number of an- tispasmodic medications currently available in Colombia. Since they are frequently used to treat this disease, *Correspondence: [email protected] we consider an evaluation of them to be important. ......................................... Received: 26/10/18 Keywords Accepted: 11/02/19 Antispasmodic, irritable bowel syndrome, pinaverium bromide, otilonium bromide, Mebeverin, trimebutine. INTRODUCTION consistency. The criteria must be met for three consecutive months prior to diagnosis and symptoms must have started Irritable bowel syndrome (IBS) is one of the most fre- a minimum of six months before diagnosis. (3, 4) quent chronic gastrointestinal functional disorders. It is There are no known structural or anatomical explanations characterized by recurrent abdominal pain associated with of the pathophysiology of IBS and its exact cause remains changes in the rhythm of bowel movements with either or unknown. Nevertheless, several mechanisms have been both constipation and diarrhea. Swelling and bloating are proposed. Altered gastrointestinal motility may contribute frequent occurrences. (1) to changes in bowel habits reported by some patients, and a IBS is divided into two subtypes: predominance of cons- combination of smooth muscle spasms, visceral hypersen- tipation (20-30% of patients) and predominance of dia- sitivity and abnormalities of central pain processing may rrhea (20-30% of patients).
    [Show full text]
  • Etats Rapides
    List of European Pharmacopoeia Reference Standards Effective from 2015/12/24 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit Y0001756 Exemestane for system suitability 1 10 mg 1 2766 Yes +5°C ± 3°C 79 ! Y0001561 Abacavir sulfate 1 20 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001552 Abacavir for peak identification 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001551 Abacavir for system suitability 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 1585 79 ! Y0000116 Acamprosate impurity A 1 50 mg 1 3-aminopropane-1-sulphonic acid 1585 Yes +5°C ± 3°C 79 ! Y0000500 Acarbose 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 August 2015 2089 Yes +5°C ± 3°C 79 ! Y0000354 Acarbose for identification 1 10 mg 1 2089 Yes +5°C ± 3°C 79 ! Y0000427 Acarbose for peak identification 3 20 mg 1 Batch 2 is valid until 31 January 2015 2089 Yes +5°C ± 3°C 79 ! A0040000 Acebutolol hydrochloride 1 50 mg 1 0871 Yes +5°C ± 3°C 79 ! Y0000359 Acebutolol impurity B 2 10 mg 1 -[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] propoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! acetamide (diacetolol) Y0000127 Acebutolol impurity C 1 20 mg 1 N-(3-acetyl-4-hydroxyphenyl)butanamide 0871 Yes +5°C ± 3°C 79 ! Y0000128 Acebutolol impurity I 2 0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! butanamide Y0000056 Aceclofenac - reference spectrum 1 n/a 1 1281 79 ! Y0000085 Aceclofenac impurity F 2 15 mg 1 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate
    [Show full text]
  • Diagnosis and Treatment of Irritable Bowel Syndrome a Review
    Clinical Review & Education JAMA | Review Diagnosis and Treatment of Irritable Bowel Syndrome A Review Michael Camilleri, MD Multimedia IMPORTANCE The prevalence of irritable bowel syndrome (IBS) in the United States is CME Quiz at between 7% and 16%, most common in women and young people, with annual direct costs jamacmelookup.com estimated at more than $1 billion dollars in the United States. Traditionally, the diagnosis of IBS has been based on the positive identification of symptoms that correlate with several different syndromes associated with disorders such as IBS diarrhea, IBS constipation, functional diarrhea, functional constipation, chronic functional abdominal pain, or bloating. Several peripheral and central mechanisms initiate gastrointestinal motor and sensory dysfunctions leading to IBS symptoms. Those dysfunctions may require evaluation in patients whose symptoms do not respond to first-line treatments. OBSERVATIONS Validation studies of consensus symptom-based criteria have identified deficiencies that favor a simpler identification of the predominant symptoms of abdominal pain, bowel dysfunction, and bloating and exclusion of alarm symptoms such as unintentional weight loss, rectal bleeding, or recent change in bowel function. Symptom-based diagnosis of IBS is enhanced with additional history for symptoms of somatoform and psychological disorders and alarm symptoms, physical examination including digital rectal examination, and screening tests to exclude organic disease (by measuring hemoglobin and C-reactive protein concentrations). The initial treatment plan should include patient education, reassurance, and first-line treatments such as fiber and osmotic laxatives for constipation, opioids for diarrhea, antispasmodics for pain and for management of associated psychological disorders. For patients who do not respond to those IBS treatments, testing for specific functional disorders may be required in a minority of patients with IBS.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Aluminum Phosphates
    Dr. Ralf Giskow, The Variety of Phosphates Jörg Lind, Erwin Schmidt Chemische Fabrik Budenheim KG, for Refractory and Technical D-55257 Buden- heim www.budenheim- Applications by the Example cfb.com of Aluminium Phosphates In 1669 the chemical element phos- Phase-I-content influences, for phorus was discovered by H. Brandt, example, the dissolution property of an alchemist. In 1694 Boyle made STPP in water. The choice of the the first phosphoric acid by dissolv- right phosphate can already be the ing phosphorus pentoxide (P2O5) in crucial point even with such a “sim- water. This was the start of the phos- ple“ phosphate like sodium tripoly- phorus chemistry. Since this time phosphate. phosphoric acid and its salts have a The next step into the direction firm place in chemistry and technical of complexity is a phosphate called applications. Phosphates are part of sodium hexametaphosphate (SHMP) our life and are used in a variety of in colloquial language. In fact, the ways also in industrial fields like chemical name is a mistake. The refractories, glass, ceramics, con- name sodium hexametaphosphate struction industry and for a lot of would stand for a sodium phosphate other technical purposes. with a ring structure (“meta”). But SHMP has a chaintype structure as can be proved. These melted glassy polyphosphates (SHMP) with pH-val- Fig. 1 Phosphates in Refractory phosphates are polyphosphates with ues between three and nine, most of FABUTIT 734, a modified STPP and Technical Industries different chain lengths. The average the products also in an instantised against a standard The most common and well known chain length and thus the properties quality (Fig.
    [Show full text]